AGITATION
Clinical trials for AGITATION explained in plain language.
Never miss a new study
Get alerted when new AGITATION trials appear
Sign up with your email to follow new studies for AGITATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to calm agitation in Alzheimer's patients
Symptom relief Recruiting nowThis study is testing whether a new oral medication called BMS-986368 can safely reduce agitation in people with Alzheimer's disease. About 120 participants will be randomly assigned to receive either the drug or a placebo to compare the effects. The main goal is to see if the dr…
Matched conditions: AGITATION
Phase: PHASE2 • Sponsor: Celgene • Aim: Symptom relief
Last updated Mar 31, 2026 12:12 UTC
-
New hope for calming Alzheimer's agitation
Symptom relief Recruiting nowThis study is testing whether an experimental drug called masupirdine can safely reduce agitation in people with Alzheimer's dementia. About 375 participants will take either the drug or a placebo pill daily for 12 weeks. Researchers will measure changes in aggressive behaviors, …
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: Suven Life Sciences Limited • Aim: Symptom relief
Last updated Mar 31, 2026 12:12 UTC
-
Could a cannabis drug calm Alzheimer's agitation?
Symptom relief Recruiting nowThis study is testing whether nabilone, a synthetic drug similar to cannabis, can safely and effectively treat agitation in people with Alzheimer's disease. Agitation is a common and distressing symptom that speeds up the need for nursing home care and increases caregiver stress.…
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
New hope for calming Alzheimer's agitation: Long-Term drug safety tested
Symptom relief Recruiting nowThis study aims to understand the long-term safety and side effects of two drug combinations, KarXT and KarX-EC, for treating agitation in people with Alzheimer's disease. It is open to 600 participants who have already completed one of two previous related studies. The main goal…
Matched conditions: AGITATION
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Mar 30, 2026 14:27 UTC
-
New skin patch could calm Alzheimer's agitation
Symptom relief Recruiting nowThis study is testing whether a skin patch containing the medication dexmedetomidine can help reduce agitation in people with Alzheimer's disease. Researchers will compare the patch to a placebo patch in 150 participants living in care facilities. The goal is to see if the patch …
Matched conditions: AGITATION
Phase: PHASE2 • Sponsor: Teikoku Pharma USA, Inc. • Aim: Symptom relief
Last updated Mar 19, 2026 14:55 UTC